SCHEMBL3524040

SCHEMBL3524040

O=c1c(Br)c(OCc2ccc(Cl)cc2)ncn1Cc1ccc(Cl)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 2/20 0.55
MAPK1 P28482 2/20 0.44
LMNA P02545 1/20 0.44
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
TSHR P16473 2/20 0.43
HPGD P15428 2/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2C19 P33261 1/20 0.43
GAA P10253 1/20 0.43
PKM P14618 1/20 0.43
HDAC6 Q9UBN7 1/20 0.42
SCD O00767 2/20 0.42
TP53 P04637 1/20 0.42
NPSR1 Q6W5P4 1/20 0.41
CYP11B1 P15538 1/20 0.41
CYP11B2 P19099 1/20 0.41
HTT P42858 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3522825 0.95 MAPK14 (0.54) MAPK14MAPK1LMNAMEN1KMT2A
SCHEMBL3524246 0.95 MAPK14 (0.54) MAPK14MAPK1LMNAMEN1KMT2A
SCHEMBL3520846 0.94 MAPK14 (0.65) MAPK14MAPK1LMNAMEN1KMT2A
SCHEMBL3520639 0.92 MAPK14 (0.48) MAPK14MAPK1LMNASMN1; SMN2TSHR
SCHEMBL3520892 0.91 MAPK14 (0.47) MAPK14MAPK1LMNASMN1; SMN2TSHR
SCHEMBL3522839 0.88 MAPK14 (0.57) MAPK14LMNAMEN1KMT2ASMN1; SMN2
SCHEMBL3526954 0.88 TP53 (0.46) MAPK14LMNAMEN1KMT2ASMN1; SMN2
SCHEMBL3524527 0.87 MAPK14 (0.60) MAPK14LMNAMEN1KMT2ASMN1; SMN2
SCHEMBL3522304 0.85 MAPK14 (0.55) MAPK14LMNAMEN1KMT2ATSHR
SCHEMBL3522147 0.84 PSMB2 (0.49) MAPK14LMNAKMT2ATSHRHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7795271-B2 Substituted pyrimidinones PHARMACIA CORPORATION (US) 2010-09-14 US disclosed
US-20090306108-A1 SUBSTITUTED PYRIMIDINONES PFIZER INC 2009-12-10 US disclosed
US-20070167621-A1 SUBSTITUTED PYRIMIDINONES PHARMACIA CORPORATION (US) 2007-07-19 US disclosed
US-7183287-B2 Substituted pyrimidinones PHARMACIA CORPORATION (US) 2007-02-27 US disclosed
US-20040242608-A1 Substituted pyrimidinones PHARMACIA LLC 2004-12-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306108-A1 SUBSTITUTED PYRIMIDINONES MAPK1, MAP3K8, MAP3K7 MAPK14 38/4885MAPK1 1/4885LMNA 3164/4885
US-20040242608-A1 Substituted pyrimidinones MAPK1, MAPK7, MAP3K8 MAPK14 29/4885MAPK1 1/4885LMNA 3198/4885
US-20070167621-A1 SUBSTITUTED PYRIMIDINONES MAPK1, MAP3K8, MAP3K7 MAPK14 38/4885MAPK1 1/4885LMNA 3164/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.